China researchers have filed for a China Invention Patent to remdesivir, a Gilead candidate to treat 2019-nCoV. According to people familiar with China patent law, they are unlikely to succeed because Gilead owns global IP for the molecule and for its use as a coronavirus treatment. The experts further noted the researchers did not file for a Compulsory Use patent, a more "heavy handed" approach that would give China authorities the right to use the drug for a dire need. The experts reasoned the choice shows China does not want to unsettle global IP standards. Instead, as the China researchers noted, if Gilead agrees to supply remdesivir, China would not choose to enforce the patent. More details....
Stock Symbol: (NSDQ: GILD)
Share this with colleagues: